Drug Profile

RSS 0343

Alternative Names: RSS-0343

Latest Information Update: 31 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Hengrui Medicine Co.
Class 1 ring heterocyclic compounds; 3-ring heterocyclic compounds; Amides; Antibronchitics; Benzene derivatives; Benzopyrans; Fluorobenzenes; Nitriles; Small molecules
Mechanism of Action Cathepsin C inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

10 Aug 2026 Reistone Biopharma Company Limited completes a phase I trial for Bronchiectasis (In volunteers) in China (PO) (NCT07289464)
10 Jul 2026 Reistone Biopharma plans a phase I trial for Bronchiectasis, Sinusitis and Chronic obstructive pulmonary disease in China (PO, Tablet) (NCT07696091)
10 Mar 2026 Phase-II clinical trials in Chronic obstructive pulmonary disease (Treatment-experienced) in China (PO) (NCT07349524)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com